Compare BZUN & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BZUN | TNYA |
|---|---|---|
| Founded | 2007 | 2016 |
| Country | China | United States |
| Employees | N/A | 70 |
| Industry | Catalog/Specialty Distribution | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 157.7M | 178.5M |
| IPO Year | N/A | 2021 |
| Metric | BZUN | TNYA |
|---|---|---|
| Price | $2.20 | $0.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $5.33 |
| AVG Volume (30 Days) | 192.1K | ★ 5.0M |
| Earning Date | 03-25-2026 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 54.96 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.10 | N/A |
| Revenue Next Year | $3.93 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.12 | $0.36 |
| 52 Week High | $4.88 | $2.35 |
| Indicator | BZUN | TNYA |
|---|---|---|
| Relative Strength Index (RSI) | 27.06 | 50.19 |
| Support Level | N/A | $0.61 |
| Resistance Level | $3.05 | $0.97 |
| Average True Range (ATR) | 0.10 | 0.10 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 11.27 | 48.45 |
Baozun Inc is engaged to provide its customers with end-to-end e-commerce solutions including the sales of apparel, home and electronic products, online store design and setup, visual merchandising and marketing, online store operations, customer services, warehousing and order fulfillment, as well as the holistic brand management, including strategy and tactic positioning, branding and marketing, retail and e-commerce operations, supply chain and logistics, and technology empowerment. It has two operating segments: E-Commerce (encompassing BEC and BZI) and Brand Management (representing BBM). The company generates maximum of its revenue from E-Commerce (encompassing BEC and BZI) segment.
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.